Lunai Bioworks Inc. (LNAI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lunai Bioworks Inc. on May 20, 2026. The filing discloses a corporate action regarding the company's capital structure rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event.
Material Changes
The primary material change announced is a 1-for-8 reverse stock split of the company's issued and outstanding common stock. Key details include:
- Effective Date: Expected to become effective at 12:01 a.m. Eastern Time on May 22, 2026.
- Trading Resumption: Common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on May 22, 2026.
- Trading Symbol: The existing symbol "LNAI" will remain unchanged.
- CUSIP Number: A new CUSIP number, 29350E302, will be assigned following the effectiveness of the split.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial performance, or specific risk factors beyond the standard implications of a reverse stock split. The action is presented as a procedural event to adjust the share count.
Investor Verification Checklist
- Verify the exact timing of the reverse stock split effectiveness (May 22, 2026, 12:01 a.m. ET).
- Confirm the new CUSIP number (29350E302) with your brokerage to ensure proper account updates.
- Review the press release (Exhibit 99.1) for details on fractional share handling, which is not detailed in the 8-K text.
- Monitor the stock price on May 22, 2026, to confirm trading begins on a split-adjusted basis under the symbol LNAI.